Vaxcyte

News

Vaxcyte's pneumococcal jab exceeds expectations

Shares in Vaxcyte have rocketed on phase 3 trial data for its pneumococcal vaccine VAX-31 that suggests it could take on rivals from Pfizer and MSD.

News

Vaxcyte's pneumococcal vaccine win points to Prevnar battle

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD.

News

Slaoui exits three more companies amid harassment fallout

Moncef Slaoui has stepped down from positions at three more companies, shortly after being dismissed from a firm owned by GlaxoSmithKline for alleged sexual harassment.

Vaxcyte's pneumococcal jab exceeds expectations

Vaxcyte's pneumococcal vaccine win points to Prevnar battle

Slaoui exits three more companies amid harassment fallout

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks